Charnwood Molecular, a UK-based preclinical discovery CRO servicing the global pharmaceutical and biopharma market, is planning a significant expansion in 2021.
 
Charnwood Molecular will continue to build on its medicinal chemistry, scale-up chemistry and custom synthesis provision, evolving its business strategy to deliver increasingly high-tech and high-value research capabilities. To enable the expansion, Charnwood Molecular recently partnered with Synova, a leading European private equity fund, providing Charnwood with additional capital to support its future development and growth, including the introduction of additional senior leadership team members to the business.
 
Charnwood will become the sole occupier of a substantial 3-storey, state-of-the-art lab facility at Charnwood Campus, Loughborough. The campus was recently designated a ‘Life Sciences Opportunity Zone’, to encourage collaboration and accelerate business growth within the Med-Tech and Biopharma industries.
 
CEO of Charnwood Molecular, Steve Allin, commented: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines.”